EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Clinical and Diagnostic Utility of Genomic Profiling for Digestive Cancers: Real-World Evidence from Japan

Marin Ishikawa iD, Kohei Nakamura iD, Ryutaro Kawano, Hideyuki Hayashi, Tatsuru Ikeda, Makoto Saito iD, Yo Niida iD, Jiichiro Sasaki iD, Hiroyuki Okuda, Satoshi Ishihara, Masatoshi Yamaguchi, Hideaki Shimada iD und 15 weitere

Cancers · 15.04.2024 · 16 (8) · 1504

DOI: 10.3390/cancers16081504 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancers, online erschienen am 15.04.2024. Verfasst von Marin Ishikawa und 26 weiteren Autor:innen. Beteiligte Einrichtung: Genomics Unit, Keio Cancer Center, Keio University School of Medicine, Integrated Medical Research Building 3-S5, 35, Shinanomachi, Shinjuku-ku, Toky…. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: JSPS KAKENHI, Research Grant from the Princess Takamatsu Cancer Research Fund, the Japan Agency for Medical Research and Development.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The usefulness of comprehensive genomic profiling (CGP) in the Japanese healthcare insurance system remains underexplored. Therefore, this large-scale study aimed to determine the usefulness of CGP in diagnosing digestive cancers. Patients with various cancer types recruited between March 2020 and October 2022 underwent the FoundationOne® CDx assay at the Keio PleSSision Group (19 hospitals in Japan). A scoring system was developed to identify potentially actionable genomic alterations of biological significance and actionable genomic alterations. The detection rates for potentially actionable genomic alterations, actionable genomic alterations, and alterations equivalent to companion diagnosis (CDx), as well as the signaling pathways associated with these alterations in each digestive cancer, were analyzed. Among the 1587 patients, 547 had digestive cancer. The detection rates of potentially actionable genomic alterations, actionable genomic alterations, and alterations equivalent to CDx were 99.5%, 62.5%, and 11.5%, respectively. APC, KRAS, and CDKN2A alterations were frequently observed in colorectal, pancreatic, and biliary cancers, respectively. Most digestive cancers, except esophageal cancer, were adenocarcinomas. Thus, the classification flowchart for digestive adenocarcinomas proposed in this study may facilitate precise diagnosis. CGP has clinical and diagnostic utility in digestive cancers.

Schlagwörter

Stichwörter der Autor:innen

adenocarcinomacancer gene panelcomprehensive genomic profilingpathological diagnosis

Autor:innen und Institutionen

  • Genomics Unit, Keio Cancer Center, Keio University School of Medicine, Integrated Medical Research Building 3-S5, 35, Shinanomachi, Shinjuku-ku, Tokyo 160-8582, Japan.
  • Department of Cancer Genome Medical Center, Hakodate Goryoukaku Hospital, 38-3, Goryoukakucho, Hakodate-shi 040-8611, Hokkaido, Japan.
  • Department of Genetic Medicine, Ibaraki Prefectural Center Hospital, 6528, Koibuchi, Kasama-shi 309-1793, Ibaraki, Japan.
  • Center for Clinical Genomics, Kanazawa Medical University Hospital, 1-1, Daigaku, Uchinada 920-0293, Ishikawa, Japan.
  • Research and Development Center for New Medical Frontiers, Kitasato University School of Medicine, 1-15-1 Kitasato, Minami-ku, Sagamihara-shi 252-0329, Kanagawa, Japan.
  • Department of Medical Oncology, Keiyukai Sapporo Hospital, 1-1 Minami, Hondori 9, Chome, Shiroishi-ku, Sapporo 003-0026, Hokkaido, Japan.

ORCID-Profile: Marin Ishikawa, Kohei Nakamura, Makoto Saito, Yo Niida, Jiichiro Sasaki, Hideaki Shimada, Takeshi Isobe, Hajime Kuroda, Kei Takeshita, Yu Sunakawa

Förderung

  • JSPS KAKENHI
  • Research Grant from the Princess Takamatsu Cancer Research Fund
  • the Japan Agency for Medical Research and Development
  • Princess Takamatsu Cancer Research Fund
  • Japan Agency for Medical Research and Development (AMED)

Zitieren

APA

Ishikawa, M., Nakamura, K., Kawano, R., Hayashi, H., Ikeda, T., Saito, M., Niida, Y., Sasaki, J., Okuda, H., Ishihara, S., Yamaguchi, M., Shimada, H., Isobe, T., Yuza, Y., Yoshimura, A., Kuroda, H., Yukisawa, S., Aoki, T., Takeshita, K., …, & Nishihara, H. (2024). Clinical and Diagnostic Utility of Genomic Profiling for Digestive Cancers: Real-World Evidence from Japan. Cancers, 16(8), 1504. https://doi.org/10.3390/cancers16081504

Vancouver

Ishikawa M, Nakamura K, Kawano R, Hayashi H, Ikeda T, Saito M, et al. Clinical and Diagnostic Utility of Genomic Profiling for Digestive Cancers: Real-World Evidence from Japan. Cancers. 2024;16(8):1504. doi:10.3390/cancers16081504

BibTeX
@article{Ishikawa2024,
  author = {Ishikawa, Marin and Nakamura, Kohei and Kawano, Ryutaro and Hayashi, Hideyuki and Ikeda, Tatsuru and Saito, Makoto and Niida, Yo and Sasaki, Jiichiro and Okuda, Hiroyuki and Ishihara, Satoshi and Yamaguchi, Masatoshi and Shimada, Hideaki and Isobe, Takeshi and Yuza, Yuki and Yoshimura, Akinobu and Kuroda, Hajime and Yukisawa, Seigo and Aoki, Takuya and Takeshita, Kei and Ueno, Shinichi and Nakazawa, Junichi and Sunakawa, Yu and Nohara, Sachio and Okada, Chihiro and Nishimiya, Ko and Tanishima, Shigeki and Nishihara, Hiroshi},
  title = {Clinical and Diagnostic Utility of Genomic Profiling for Digestive Cancers: Real-World Evidence from Japan},
  journal = {Cancers},
  year = {2024},
  volume = {16},
  number = {8},
  pages = {1504},
  doi = {10.3390/cancers16081504}
}
Kostenlos starten →